Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) will likely be posting its Q4 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($1.20) per share and revenue of $1.50 million for the quarter. Parties may review the information on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Friday, September 18, 2026 at 11:30 AM ET.
Palatin Technologies Price Performance
NYSEAMERICAN PTN opened at $10.48 on Monday. Palatin Technologies has a 1-year low of $5.61 and a 1-year high of $31.00. The business has a 50 day moving average price of $9.48 and a 200 day moving average price of $15.27.
Hedge Funds Weigh In On Palatin Technologies
Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new stake in shares of Palatin Technologies in the fourth quarter valued at approximately $272,000. Jane Street Group LLC acquired a new stake in Palatin Technologies during the 4th quarter valued at $166,000. Bleichroeder LP acquired a new stake in Palatin Technologies during the 4th quarter valued at $120,000. RA Capital Management L.P. purchased a new position in Palatin Technologies during the fourth quarter worth $1,077,000. Finally, Logos Global Management LP purchased a new position in Palatin Technologies during the fourth quarter worth $2,153,000. 11.50% of the stock is currently owned by hedge funds and other institutional investors.
About Palatin Technologies
Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.
Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.
See Also
- Five stocks we like better than Palatin Technologies
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.png){kind=logo}
